FDA pro­mo­tions watch­dog de­liv­ers first warn­ing let­ter of the year to As­traZeneca over Breztri mar­ket­ing

As­traZeneca has re­ceived the first warn­ing let­ter of the year from the FDA’s pro­mo­tion po­lice over al­leged ef­fi­ca­cy claims for its COPD med Breztri Aeros­phere …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER